Thrombosis is the common underlying mechanism in a quarter of global mortality. Cardiovascular diseases are responsible for 45% of all mortality in Europe. Venous thromboembolism (VTE) is an important cause of death in hospitalized patients and treatment of non-fatal symptomatic VTE and related long-term morbidities are associated with a considerable health care costs. VTE carries...

Faculty

• Ajay K. Kakkar , BSc, MBBS, PhD, FRCS

Selection and duration of appropriate therapy for VTE can be improved in clinical practice. Physicians remain reluctant to prescribe anticoagulant (AC) prophylaxis in a large proportion of the population at risk for thromboembolic stroke.
Risk factors for bleeding in patients receiving thromboprophylaxis must be recognized by the treating physician. The management of VTE...

Faculty

• Ajay K. Kakkar , BSc, MBBS, PhD, FRCS

The registry captures real-world data and provides information on adherence to national and international guidelines and identifies treatment deficiencies as well as good practice. The insights of the GARFIELD-VTE and other registries in VTE are important in bridging the gap between contemporary research and clinical practice and also serve to increase awareness of the importance...

Faculty

• Alexander G. Turpie , MB, FRCP, FACP, FACC, FRCPC

Important new evidence has recently emerged on the treatment of cancer-associated thrombosis. Patients with cancer carry an increased risk of developing VTE because of tumor- and treatment-mediated hypercoagulability. Clinical risk factors for VTE in cancer include the primary site of cancer, use of systemic therapy (chemotherapy, erythropoiesis-stimulating agents, exogenous...

Faculty

• Gerald A. Soff , MD

Understanding the role of anticoagulant therapy in the prevention of stroke is a prerequisite for initiating a proper treatment regimen. Physicians remain reluctant to prescribe anticoagulant prophylaxis in a large proportion of the population at risk for stroke in part due to misperception of thrombotic risk and concern about bleeding complications, especially among the elderly.

Faculty

• Christopher B. Granger , MD, FACC, FAHA

International studies such as Global Anticoagulant Registry in the FIELD of atrial fibrillation (GARFIELD-AF) have been important in describing everyday antithrombotic treatment patterns in patients newly diagnosed with non-valvular AF and one or more additional investigator-defined risk factor for stroke. These data have provided valuable insights into the characteristics, risk...

Faculty

• A John Camm , MD, QHP, MD, FRCP, FACC, FESC

The management of VTE frequently carries significant clinical challenges. Risk factors for bleeding in patients receiving thromboprophylaxis must be recognized by the treating physician. There is a need for improving the perception of strategies in prevention of thromboembolic stroke and concern about bleeding complications, especially among the elderly. The weighing of...

Faculty

• Craig M. Kessler , MD

Selection and duration of appropriate therapy for venous thromboembolism (VTE) can be improved in clinical practice. Physicians remain reluctant to prescribe anticoagulant (AC) prophylaxis in a large proportion of the population at risk for thromboembolic stroke. 

Risk factors for bleeding in patients receiving thromboprophylaxis must be recognized by the treating...

Faculty

• Kenneth A. Bauer , MD
• Sylvia Haas , MD, PhD
• Giancarlo Agnelli , MD

VTE is a potentially preventable and treatable condition with the use of anticoagulation therapy. Management aims to reduce mortality and the risks of recurrence and long-term complications. The risk of recurrence is highest in the first 6-12 months after cessation of anticoagulant therapy but a heightened risk persists for at least ten years. Up to 25% of all VTE events occur in...

Faculty

• Christopher B. Granger , MD, FACC, FAHA